Press Releases Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
1.290 ^USD	-11.64%		-16.23%	-6.52%

Jun. 02	Neuronetics, Inc. Announces Appointment of Robert Greene to Senior Vice President Sales, Effective June 1, 2026	CI
May. 22	Neuronetics, Inc. Appoints Francis X. Brown III as Interim Principal Financial Officer, Effective May 5, 2026	CI

Press Releases

Jun. 02	Neuronetics Appoints Robert Greene as Senior Vice President Sales	AQ
Jun. 02	Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026	GL
May. 14	Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment	GL
May. 05	Neuronetics : STIM Corporate Presentation May 2026	PU
May. 05	Neuronetics: Q1 Earnings Snapshot	AQ
May. 05	Neuronetics Reports First Quarter 2026 Financial and Operating Results	AQ
Apr. 29	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
Apr. 21	Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call	AQ
Apr. 13	Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners	GL
Apr. 07	Neuronetics Comments on Letter from Pointillist Family Office	AQ
Apr. 06	Neuronetics Announces Chief Financial Officer Transition	AQ
Apr. 06	Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business	PR
Mar. 17	Neuronetics: Q4 Earnings Snapshot	AQ
Mar. 17	Neuronetics : STIM Corporate Presentation March 2026	PU
Mar. 17	Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results	AQ
Mar. 17	Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer	AQ
Mar. 03	Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call	AQ
Feb. 10	Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results	AQ
Nov. 20	Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference	AQ
Nov. 12	TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression	GL
Nov. 04	Neuronetics: Q3 Earnings Snapshot	AQ
Nov. 04	Neuronetics : STIM Corporate Presentation November 2025	PU
Nov. 04	Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan	AQ
25-10-31	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
25-10-30	Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence	GL